Syndax Pharmaceuticals, Inc. Investment Income, Interest
Syndax Pharmaceuticals, Inc. (SNDX) reported Investment Income, Interest of $3.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-06-30 was $3.75M, a 37.04% decline year-over-year.
- Syndax Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-03-31 was $3.56M, a 50.42% decline year-over-year.
- Syndax Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-12-31 was $4.33M, a 39.11% decline year-over-year.
- Syndax Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-09-30 was $5.27M, a 3.18% decline year-over-year.
- Syndax Pharmaceuticals, Inc. investment income, interest for fiscal 2025 was $22.73M, a 12.88% decline from fiscal 2024.
- Syndax Pharmaceuticals, Inc. investment income, interest for fiscal 2024 was $26.09M, a 23.28% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. investment income, interest for fiscal 2023 was $21.16M, a 260.41% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. investment income, interest for fiscal 2022 was $5.87M, a 1357.07% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.75M 10-Q · filed 2026-08-04 | $7.31M 10-Q · filed 2026-08-04 | $11.63M derived: sum of 3 quarters · filed 2026-08-04 | $16.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.56M 10-Q · filed 2026-04-30 | $7.89M derived: sum of 2 quarters · filed 2026-04-30 | $13.16M derived: sum of 3 quarters · filed 2026-04-30 | $19.11M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.60M derived: sum of 2 quarters · filed 2026-02-26 | $15.55M derived: sum of 3 quarters · filed 2026-08-04 | $22.73M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.27M 10-Q · filed 2025-11-03 | $11.22M derived: sum of 2 quarters · filed 2026-08-04 | $18.40M 10-Q · filed 2025-11-03 | $25.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.95M 10-Q · filed 2026-08-04 | $13.13M 10-Q · filed 2026-08-04 | $20.24M derived: sum of 3 quarters · filed 2026-08-04 | $25.68M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $7.18M 10-Q · filed 2026-04-30 | $14.29M derived: sum of 2 quarters · filed 2026-04-30 | $19.73M derived: sum of 3 quarters · filed 2026-04-30 | $26.02M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.55M derived: sum of 2 quarters · filed 2026-02-26 | $18.83M derived: sum of 3 quarters · filed 2026-02-26 | $26.09M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.44M 10-Q · filed 2025-11-03 | $11.73M derived: sum of 2 quarters · filed 2025-11-03 | $18.98M 10-Q · filed 2025-11-03 | $24.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $6.28M 10-Q · filed 2025-08-04 | $13.54M 10-Q · filed 2025-08-04 | $19.09M derived: sum of 3 quarters · filed 2026-02-26 | $24.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $7.26M 10-Q · filed 2025-05-05 | $12.81M derived: sum of 2 quarters · filed 2026-02-26 | $18.15M derived: sum of 3 quarters · filed 2026-02-26 | $23.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.89M derived: sum of 2 quarters · filed 2026-02-26 | $16.09M derived: sum of 3 quarters · filed 2026-02-26 | $21.16M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.34M 10-Q · filed 2024-11-05 | $10.54M derived: sum of 2 quarters · filed 2024-11-05 | $15.61M 10-Q · filed 2024-11-05 | $18.60M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $5.19M 10-Q · filed 2024-08-01 | $10.27M 10-Q · filed 2024-08-01 | $13.26M derived: sum of 3 quarters · filed 2025-03-03 | $15.04M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $5.08M 10-Q · filed 2024-05-08 | $8.06M derived: sum of 2 quarters · filed 2025-03-03 | $9.85M derived: sum of 3 quarters · filed 2025-03-03 | $10.72M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $4.77M derived: sum of 2 quarters · filed 2025-03-03 | $5.65M derived: sum of 3 quarters · filed 2025-03-03 | $5.87M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.78M 10-Q · filed 2023-11-02 | $2.66M derived: sum of 2 quarters · filed 2023-11-02 | $2.88M 10-Q · filed 2023-11-02 | $2.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $878.00K 10-Q · filed 2023-08-03 | $1.10M 10-Q · filed 2023-08-03 | $1.19M derived: sum of 3 quarters · filed 2024-02-27 | $1.28M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $224.00K 10-Q · filed 2023-05-08 | $315.00K derived: sum of 2 quarters · filed 2024-02-27 | $398.00K derived: sum of 3 quarters · filed 2024-02-27 | $506.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $174.00K derived: sum of 2 quarters · filed 2024-02-27 | $282.00K derived: sum of 3 quarters · filed 2024-02-27 | $403.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $83.00K 10-Q · filed 2022-11-03 | $191.00K derived: sum of 2 quarters · filed 2022-11-03 | $312.00K 10-Q · filed 2022-11-03 | $417.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $108.00K 10-Q · filed 2022-08-08 | $229.00K 10-Q · filed 2022-08-08 | $334.00K derived: sum of 3 quarters · filed 2023-02-28 | $511.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $120.00K 10-Q · filed 2022-05-09 | $226.00K derived: sum of 2 quarters · filed 2023-02-28 | $403.00K derived: sum of 3 quarters · filed 2023-02-28 | $628.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $283.00K derived: sum of 2 quarters · filed 2023-02-28 | $508.00K derived: sum of 3 quarters · filed 2023-02-28 | $841.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $177.00K 10-Q · filed 2021-11-15 | $402.00K derived: sum of 2 quarters · filed 2021-11-15 | $735.00K 10-Q · filed 2021-11-15 | $957.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $225.00K 10-Q · filed 2021-08-09 | $558.00K 10-Q · filed 2021-08-09 | $780.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.18M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $333.00K 10-Q · filed 2021-05-11 | $555.00K derived: sum of 2 quarters · filed 2022-03-01 | $950.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.45M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $617.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.12M derived: sum of 3 quarters · filed 2022-03-01 | $1.57M 10-K · filed 2022-03-01 |
| 2019-09-30 | $395.00K 10-Q · filed 2020-11-05 | $896.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.35M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $501.00K 10-Q · filed 2020-08-06 | $953.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $452.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $1.94M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |